论文部分内容阅读
目的探讨天冬酰胺内肽酶(Legumain)在宫颈癌中的表达及Legumain高表达的相关危险因素。方法纳入行宫颈癌筛查、初筛阳性并行阴道镜下活检的患者187例,根据诊断结果分为正常组(n=84)、癌前病变组(CINⅠ~Ⅲ)(n=62)和宫颈癌组(Ⅰ~Ⅳ,FIGO分期)(n=41),通过免疫组化检测Legumain在不同病变组织中的表达,并进一步分析影响Legumain高表达的相关危险因素。结果宫颈癌组中Legumain表达明显高于正常组和癌前病变组(P<0.05),但正常组与癌前病变组间表达差异无统计学意义(P>0.05)。肿瘤组织学分型[1.483(1.258~2.950),P=0.019]和宫颈癌FIGO分期[2.072(1.313~3.264),P=0.011]是Legumain在宫颈癌中高表达的相关危险因素。结论Legumain在宫颈癌中呈高表达,与其组织学分型及临床分期存在相关性。
Objective To investigate the expression of Legumain in cervical cancer and the related risk factors of Legumain overexpression. Methods A total of 187 patients with cervical cancer undergoing primary colposcopy and colposcopic biopsy were enrolled in this study. According to the results of the diagnosis, they were divided into normal group (n = 84), precancerous lesions group (CINⅠ ~ Ⅲ) (n = 62) Cancer group (Ⅰ ~ Ⅳ, FIGO staging) (n = 41). The expression of Legumain in different pathological tissues was detected by immunohistochemistry and the related risk factors influencing Legumain overexpression were further analyzed. Results The expression of Legumain in cervical cancer group was significantly higher than that in normal group and precancerous lesions group (P <0.05), but there was no significant difference between normal group and precancerous lesions group (P> 0.05). Tumor histological type [1.483 (1.258-2.950), P = 0.019] and FIGO staging of cervical cancer [2.072 (1.313-3.264), P = 0.011] were associated risk factors for the high expression of Legumain in cervical cancer. Conclusion Legumain is highly expressed in cervical cancer, which is correlated with its histological type and clinical stage.